Free

Details

  • Released
  • Updated
  • March 6, 2013
  • November 21, 2024

Features

AnticoagEvaluator screenshot #1 for iPhone
AnticoagEvaluator screenshot #2 for iPhone
AnticoagEvaluator screenshot #3 for iPhone
AnticoagEvaluator screenshot #4 for iPhone
iphone
ipad
🖼️Get Icon
Icons↘︎

About

This medical app assists healthcare professionals in making informed decisions regarding antithrombotic therapy for patients with non-valvular atrial fibrillation. It calculates patient risk factors, provides guideline-driven therapy recommendations, and helps optimize anticoagulant dosages.

Calculate renal function and stroke/bleed risk
Review ACC/AHA/HRS guideline therapy
Generate individualized antithrombotic risk
Optimize DOAC dosages
Based on SPARC Tool
Show original description

What's New in AnticoagEvaluator

5.0.0.7

November 21, 2024

This app has been updated with an enhanced Risk Bar which showcases CHA2DS2-VASc and ATRIA stroke risk point scores for all patients alongside the stroke risk magnitude percentage. In addition, a visual display bug was fixed and standard notification functionality was incorporated.

More

User reviews

Useless now.

Since updating to new risk models… the app doesn’t display and actual CHADs-Vasc Score. I understanding what you are going for, but this honestly makes the app less useful and no longer my go-to. Such a shame. Used it for many years and loved it prior to this change.

Credible?

Results seem very one-sided. Wonder where funding came from? If results always show same anticoag, why have app?

Great app very useful

The ACC web team is so responsive!!! App works great now on iPhone 6

Loss of function in iOS 8

Can no longer select and receive details for a particular therapy option. This needs to be fixed.

Temporary Workaround

It's become less functional since the IOS 8; you can no longer choose a therapy and see the details of its usefulness or the lack thereof. However, here is temporary workaround until they fix it: after selecting the risk factors for your patient, you click on the email icon and it will give you the relative risk reductions for all of the therapies.
I know it's inelegant but is still functional.
Hopefully, they will fix it soon.
Show more

Developer apps

FAQ

What is AnticoagEvaluator used for?

AnticoagEvaluator is a medical tool designed to help healthcare professionals make informed decisions about antithrombotic therapy for patients with non-valvular atrial fibrillation. It aids in calculating patient risks and reviewing guideline-driven treatment options.

What kind of risks does AnticoagEvaluator assess?

The app calculates a patient's renal function and assesses their risk of ischemic stroke, thromboembolism, and bleeding. This information is crucial for tailoring antithrombotic therapy.

Does AnticoagEvaluator provide treatment guidance?

Yes, it reviews ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention. It also generates individualized risk assessments for different antithrombotic therapy options based on clinical trials.

How does AnticoagEvaluator help with DOACs?

The app improves the accurate use of Direct Oral Anticoagulants (DOACs) by providing adjusted dosages. These dosages are fine-tuned for renal and other patient characteristics, based on prescribing information.

What is the basis for AnticoagEvaluator?

AnticoagEvaluator is based on the SPARC Tool, which was developed by Peter Loewen, ACPR, Pharm.D., FCSHP. The SPARC Tool can be accessed online at www.sparctool.com.

What is the user rating for AnticoagEvaluator?

AnticoagEvaluator has a user rating of 2.3 stars from 3 ratings. This indicates a mixed to negative reception from its current user base.

On which devices can AnticoagEvaluator be used?

AnticoagEvaluator is available for iPhone, iPad, and iPod devices. It is designed for use on Apple's iOS platform.

How often is AnticoagEvaluator updated?

The latest version of AnticoagEvaluator is 5.0.0.7, which was last updated on November 21, 2024. This suggests a recent update and ongoing maintenance by the developer.